Abstracts

1112 – PositiveLinks for Youth (PL4Y): Promising Results of a Pilot mHealth Intervention for Youth With HIV

Background Youth and emerging adults with HIV 18-29yo (YWH) face challenges in engaging in care and achieving virologic suppression. Many YWH seek mobile health (mHealth) interventions to support HIV care self-management. We used human centered design to engage YWH in the development of PositiveLinks for Youth (PL4Y), an mHealth intervention encouraging empowerment and connection between…

983 – Long-Acting Cabotegravir PrEP Among Adolescent Girls and Young Women: Pilot Results, Mozambique 2025

Background Mozambique has a high HIV incidence, with adolescent girls and young women (AGYW) accounting for 27% of the estimated 91,644 annual infections in 2024. Oral pre-exposure prophylaxis (PrEP) has been implemented in Nampula Province since 2019. In 2024, 13,585 AGYW in Nampula initiated oral PrEP, however, challenges persist, with only 23% remaining on PrEP…

741 – SARS-CoV-2 Respiratory Viral Coinfection Severity in Hospitalized Canadian Children: An IMPACT Study

Background The co-circulation of SARS-CoV-2 with other respiratory viruses raised concerns that coinfections may increase pediatric COVID-19 severity. Evidence mainly derives from critically ill patients, where testing likely underestimated milder cases. We assessed the epidemiology, clinical features, and outcomes of SARS-CoV-2 coinfections versus monoinfections in hospitalized children, accounting for hospital testing practices. Methods We analyzed…

767 – Association of CMV Viremia, IL-10 Responses, and 2-Week Mortality in Cryptococcal Meningitis

Background CMV viremia is strongly associated with increased mortality in persons with advanced HIV disease, particularly those with cryptococcal meningitis. It is unclear if CMV viremia is driving HIV-associated mortality, or if CMV serves as a sensitive biomarker of HIV-related immune dysfunction. We hypothesized that the upregulation of anti-inflammatory cytokines may provide a mechanistic explanation…

513 – Phase III Efficacy and Safety of Switch From B/F/TAF to Single-Tablet BIC/LEN in ARTISTRY-2

Background Although single tablet regimens (STRs) have transformed the HIV treatment landscape, new and effective treatment options with novel mechanisms of action are still required to meet the diverse needs of people with HIV (PWH). A new STR of bictegravir (BIC), an integrase strand-transfer inhibitor, and lenacapavir (LEN), a first-in-class capsid inhibitor, is being investigated for safety and…

790 – Population PK Analyses Predict CAB LA Dose Adjustments Are Not Required for Pregnant Women

Background CAB LA every-2-months is approved for use in pre-exposure prophylaxis (PrEP) and the treatment of HIV infection. Pregnancy can alter drug clearance and protein binding, affecting total and unbound drug concentrations. A pregnancy population PK (PPK) model was developed, and exploratory analysis of unbound CAB concentrations was performed to support dosing recommendations for CAB…

572 – Optimized LNP-Induced Viral Outgrowth Assay to Quantify bNAb Sensitivity in the HIV Latent Reservoir

Background Broadly neutralizing antibodies (bNAbs) are currently being evaluated in clinical trials for HIV treatment and cure as immunomodulatory alternatives to standard antiretroviral therapy (ART). Existing methods are insufficient to accurately predict bNAb sensitivity of HIV-1 in vivo, especially for ART-treated individuals. In pursuit of a rapid, sensitive, and scalable pre-screening method, we report the…

325 – Evidence for Silent Mpox Transmission in Healthy Nigerian Adults

Background The 2022 multi-country mpox outbreak, driven by MPXV Clade IIb, spread to over 100 countries and highlighted uncertainties around the role of residual smallpox-derived immunity and silent transmission in shaping present-day susceptibility. In West Africa, where historical smallpox vaccination campaigns ended in 1980, large unvaccinated cohorts now coexist with older vaccinated individuals, yet the…

344 – Opioid Use Disorder Associates With Reduced HIV Reservoirs but Elevated Inflammation

Background Opioid use disorder (OUD) is highly prevalent among persons with HIV-1 (PWH). While opioids modulate the immune system, their impact on the HIV-1 reservoir during antiretroviral therapy (ART) remains unclear. We leveraged the OPIS cohort to compare reservoir features, immune milieu, and HIV-specific responses in ART-treated PWH with or without OUD. Methods We studied…